Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011881 (
diabetic nephropathy
)
10,836
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The development of
proliferative diabetic retinopathy
was studied in three cohorts consisting of 292 patients with recent juvenile-onset, type I (insulin-dependent) diabetes who were followed 20-40 yr beginning in 1939, 1949, and 1959. The risk of this severe eye complication was almost nonexistent during the first 10 yr of diabetes, rose abruptly to its maximum level (approximately 30/100 person-years), and remained at that level for the next 25 yr. This pattern did not vary with sex, age at onset of diabetes, or level of glycemic control during the first 5 yr of diabetes. However, the risk of proliferative retinopathy was strongly related to the level of glycemic control during the several years preceding onset of this complication. This was a dose-dependent relationship, with patients in the highest quartile of the distribution of the index of frequency of hyperglycemia having a 10-fold higher risk than individuals in the lowest quartile. A virtually identical pattern was observed in patients who developed diabetes in 1959 as was observed in those who developed diabetes in 1949 or 1939. In contrast,
diabetic nephropathy
as evidenced by persistent proteinuria showed a lower incidence in the 1959 than in the 1939 cohort. In conclusion, these incidence data do not support the notion that the risk of proliferative retinopathy is mainly a function of duration of diabetes. Instead, the pattern of occurrence of this severe eye complication in type I diabetes suggests that the process leading to the development of proliferative retinopathy consists of two or more stages and that progression through each stage may be governed by different factors.
...
PMID:Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a 40-yr follow-up study. 376 14
We report two patients with terminal renal failure secondary to
diabetic nephropathy
treated with cadaveric kidney transplantation. Neither of these patients had peripheral vascular disease or peripheral neuropathy. There was a
proliferative diabetic retinopathy
with hemorrhages and exudates in one patient and only background diabetic changes in the ocular fundi of the other; there have been no significant changes in visual acuity or retinopathy in either patient following the transplantation. Both have good kidney function after 8 and 15 months and are completely rehabilitated.The requirement for insulin decreased in both patients during the period of renal insufficiency and increased following transplantation; this seemed to be related to the large dose of steroids given because now that a maintenance level of steroids has been established, both patients require the same dosage of insulin as they did before the onset of renal insufficiency.
...
PMID:Treatment of renal failure from diabetic nephropathy with cadaveric homograft. 457 72
On 42 patients (25 males, 17 females) at the age of 46.1 +/- 13.4 years with a
proliferative diabetic retinopathy
clinical and laboratory examinations were performed for the proof of a renal lesion. This disease was found in 59.5% of the cases. In the foreground of the pathological findings were a proteinuria, a restriction of the creatinine clearance and of the concentration power of the kidneys as well as the hypertension. The
diabetic nephropathy
had its peak of frequency between the 50th and 60th year of age and showed significant relations to the duration of diabetes as well as to be early age of manifestation. Close ophthalmological and nephrological examinations, particularly of the juvenile diabetics, should render possible an early recognition and treatment of the diabetic microangiopathy.
...
PMID:[Kidney changes in patients with proliferative diabetic retinopathy]. 648 27
A 24-year-old woman had insulin-dependent juvenile diabetes for 15 years. She developed Sheehan's syndrome (postpartum pituitary necrosis) and
diabetic nephropathy
at 20 years of age. She had multiple sessions of argon laser photocoagulation for
proliferative diabetic retinopathy
. Histologically, loss of outer retina and pigmented epithelium occurred at the laser sites. Trypsin retinal digest preparations revealed microaneurysms and markedly decreased numbers of pericytes. The kidneys displayed nodular glomerulosclerosis (Kimmelstiel-Wilson syndrome). The anterior pituitary showed cystic degeneration and old hemorrhage.
...
PMID:Histopathology of argon laser photocoagulation in juvenile diabetic retinopathy. 668 74
Results of clinical and laboratory examinations of 161 diabetics are presented. The main factors or risk of nonproliferative diabetic retinopathy are the duration and degree of compensation of diabetes mellitus, development and stage of
diabetic nephropathy
, the latter factor replacing in experiments with simulation of diabetic retinopathy the level of arterial hypertension, and the blood serum content of high-density lipoprotein cholesterol and ratio of total cholesterol to high-density lipoprotein cholesterol. The factors of risk of
proliferative diabetic retinopathy
are duration and degree of compensation of diabetes mellitus, development and stage of diabetic retinopathy with this latter factor replacing in simulation of diabetic retinopathy the level of arterial hypertension, and the blood serum levels of triglycerides, low-density lipoprotein cholesterol, fibrinogen, soluble fibrin-monomer complexes, as well as fibrinolytic activity.
...
PMID:[Clinical and epidemiological aspects of diabetic retinopathy and its relationship with diabetic nephropathy]. 865 71
Hypercholesterolemia is a major determinant of the decline of renal function in patients with diabetes. Apolipoprotein E polymorphism may influence the metabolism of lipoprotein in diabetic patients. The purpose of this study was to investigate the association between genetic polymorphisms in apolipoprotein E and the progression of
diabetic nephropathy
in patients with non-insulin-dependent diabetes mellitus over a 10-year period (13 to 37 years; median, 20 years). Subjects with a stable renal function without overt proteinuria had a higher cholesterol level, lower incidences of hypertension and
proliferative diabetic retinopathy
, and a higher frequency of the E4 allele than subjects with a decline in renal function (end-stage renal failure requiring dialysis treatment). In the diabetic patients, the apolipoprotein E4 carriers had a higher cholesterol level than did the noncarriers. The survival rate from renal disease in the apolipoprotein E4 carriers was higher than in the noncarriers among the diabetic patients. Apolipoprotein E polymorphism and hypertension were identified as independent risk factors for the progression to renal failure. Results indicate that apolipoprotein E polymorphism is associated with the progression of
diabetic nephropathy
. Presence of the apolipoprotein E4 allele is a protective factor, and other alleles are risk factors.
...
PMID:Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. 953 Nov 84
We studied 68 Japanese NIDDM patients (38 men and 30 women), aged 56.9+/-1.2 years (range 33-75 years), with a BMI of 23.1+/-0.5 kg/m2 without hypertension, dyslipidemia, and diabetic macroangiopathy for evaluating the relationship between serum soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and the severity of diabetic retinopathy. Fundus examination was performed by an ophthalmologist using an ophthalmoscope, and the findings were graded as: (1) no signs of diabetic retinopathy (NDR), (2) background diabetic retinopathy (BDR), or (3)
proliferative diabetic retinopathy
(
PDR
). Serum sVCAM-1 levels were measured in duplicate by enzyme-linked immunosorbent assay using the soluble VCAM-1 KIT (R&D Systems Ltd., Ablingdon, Oxfordshire, UK). There was no difference in serum sVCAM-1 levels between patients with BDR (n = 17) and patients with NDR (n = 40) (1035.3+/-104.4 and 978.8+/-48.9 ng/ml, respectively, P = 0.8), but patients with
PDR
(n = 11) showed a significant increase of serum sVCAM-1 levels compared with patients with NDR (1281.8+/-166.3 and 978.8+/-48.9 ng/ml, respectively, P = 0.02). Although serum sVCAM-1 levels were correlated, not only with age but also with the known diabetic duration (r = 0.39, P = 0.001, and r = 0.40, P = 0.0007, respectively), age-adjusted sVCAM-1 levels were still significantly higher in the
PDR
group than in the NDR group. In contrast. serum sVCAM-1 levels were not related to the presence of
diabetic nephropathy
or HbA1c levels. Our results suggest that sVCAM-1 might be implicated in the development of the diabetic retinopathy, and measurement of serum sVCAM-1 levels in NIDDM patients maybe clinically useful for assessing the severity and possibly the activity of diabetic retinopathy.
...
PMID:Elevated serum levels of soluble vascular cell adhesion molecule-1 in NIDDM patients with proliferative diabetic retinopathy. 988 35
The development of
diabetic nephropathy
shows remarkable variation among individuals. Therefore, not only hyperglycemia but also genetic factors may contribute to the development of
diabetic nephropathy
Heparan sulfate proteoglycan (HSPG) is thought to play an important role as a component of the charge selectivity barrier in the glomerular basement membrane. Recently, a BamHI restriction fragment length polymorphism (RFLP) in the HSPG gene (HSPG2) was reported to be associated with
diabetic nephropathy
in Caucasian insulin-dependent diabetes mellitus (IDDM). The aim of the present study was to examine the contribution of the BamHI HSPG2 polymorphism to the development of
diabetic nephropathy
in Japanese non-insulin-dependent diabetes mellitus (NIDDM). For this purpose, we recruited 102 patients with
diabetic nephropathy
and 64 age-matched patients without
diabetic nephropathy
from Japanese NIDDM patients. Since all the subjects had
proliferative diabetic retinopathy
, it seems likely that they would be exposed to hyperglycemia for a long time. In the present study, the BamHI HSPG2 genotype and allele frequencies were not significantly different between the patients with nephropathy and the patients without nephropathy. Therefore, we conclude that the BamHI HSPG2 polymorphism is not associated with the development of
diabetic nephropathy
in Japanese NIDDM.
...
PMID:Lack of association between the heparan sulfate proteoglycan gene polymorphism and diabetic nephropathy in Japanese NIDDM with proliferative diabetic retinopathy. 1058 28
To determine the relationship between plasma Lp(a) concentration and the risk of developing diabetic retinopathy, 341 Type 1 diabetic patients underwent an annual retinal fluorescein angiography and were assigned to one of 3 groups according to the stage of their diabetic retinopathy: no retinopathy (NR), non-
proliferative diabetic retinopathy
(N-PDR), or
proliferative diabetic retinopathy
(
PDR
). One hundred and twenty-three Type 1 diabetic patients had no retinopathy, 188 had N-
PDR
and 30 had
PDR
. The ages of the three groups and the duration of diabetes were significantly different. Hypertension, microalbuminuria and
diabetic nephropathy
were more frequent in
PDR
than in NR or N-
PDR
(p < 0.0001). Plasma HbA1c was higher in
PDR
than in NR or N-
PDR
(p < 0.01). Type 1 patients who had been diabetic for at least 20 years included 30 NR, 108 N-
PDR
and 24
PDR
. Type 1 diabetic patients with
PDR
had microalbuminuria and macroproteinuria more frequently than other patients (p < 0.0001 and 0.01, respectively). Type 1 diabetic patients with
PDR
had the highest median plasma Lp(a) and the highest frequency of Lp(a) above 30 mg/dl (p < 0.05). Multivariate analysis carried out in Type 1 diabetic patients with a duration of diabetes of at least 20 years showed that microproteinuria, HbA1c and Lp(a) accounted significantly for 21% of variance in retinal status. Lp(a) above 30 mg/dl was related to the risk of developing
PDR
(OR = 8.40, p < 0.05). Lipoprotein(a) appears to be associated with the severity of diabetic retinopathy in Type 1 diabetic patients, and particular attention should be paid to those with Lp(a) above 30 mg/dl and pre-proliferative retinopathy.
...
PMID:Severity of diabetic retinopathy is linked to lipoprotein (a) in type 1 diabetic patients. 1059 64
The finding that glomerular mesangial cells produce human type I collagen suggests that the serum levels of carboxy-terminal propeptide of human type I procollagen (P1CP) may reflect the severity of
diabetic nephropathy
. We therefore investigated the relationship between serum P1CP levels and the extent of diabetic complications in 100 patients (46 males and 54 females) with Type 2 diabetes and in 64 healthy subjects. Serum P1CP was determined by radioimmunoassay. In diabetes, we defined P1CP levels less than 142 ng/ml as a normal P1CP group (group A), whereas we defined them as equal to or greater than 142 ng/ml as a high P1CP group (group B). The diabetic patients had significantly elevated serum P1CP levels compared with the controls. The prevalence of hypertension,
proliferative diabetic retinopathy
or macroalbuminuria was significantly higher in group B than in group A. Serum P1CP levels showed a significant positive correlation with urinary albumin excretion, but not with fasting blood glucose, glycosylated hemoglobin A(1c) or serum osteocalcin. Macroalbuminuric patients showed significantly higher P1CP levels than the normoalbuminuric patients. In patients in the absence of
diabetic nephropathy
, no significant differences of P1CP levels were found among the severity of diabetic retinopathy. The present results suggest that serum P1CP levels reflect the progression of
diabetic nephropathy
in patients with Type 2 diabetes.
...
PMID:Serum levels of carboxy-terminal propeptide of human type I procollagen are an indicator for the progression of diabetic nephropathy in patients with type 2 diabetes mellitus. 1070 96
1
2
3
Next >>